Who are Edoxaban plus Single Antiplatelet Agent's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/edoxaban-plus-single-antiplatelet-agent.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Edoxaban plus Single Antiplatelet Agent — Competitive Intelligence Brief

Edoxaban plus Single Antiplatelet Agent (Edoxaban plus Single Antiplatelet Agent) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Factor Xa inhibitor + antiplatelet agent combination. Area: Cardiovascular.

marketed Factor Xa inhibitor + antiplatelet agent combination Factor Xa (edoxaban component); P2Y12 or COX-1 (antiplatelet component, depending on agent) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Edoxaban plus Single Antiplatelet Agent (Edoxaban plus Single Antiplatelet Agent) — Gi-Byoung Nam. Edoxaban inhibits Factor Xa to prevent blood clot formation, while a single antiplatelet agent (such as aspirin or clopidogrel) blocks platelet aggregation, providing dual antithrombotic protection.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Edoxaban plus Single Antiplatelet Agent TARGET	Edoxaban plus Single Antiplatelet Agent	Gi-Byoung Nam	marketed	Factor Xa inhibitor + antiplatelet agent combination	Factor Xa (edoxaban component); P2Y12 or COX-1 (antiplatelet component, depending on agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Factor Xa inhibitor + antiplatelet agent combination class)

Gi-Byoung Nam · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Edoxaban plus Single Antiplatelet Agent — Competitive Intelligence Brief. https://druglandscape.com/ci/edoxaban-plus-single-antiplatelet-agent. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab